CASP3 and neoplasm: Furthermore, we demonstrate that treatment with enitociclib triggers apoptosis, which leads to tumor regression because increases in caspase-3 cleavage were observed as early as 8 hours postdose and dose-dependent antitumor efficacy and tumor-outgrowth control in the SU-DHL-10 in vivo model.